Abstracts - Orals, Featured Poster Presentations, and Posters
SUN 524-553-Male Reproductive Endocrinology
Bench to Bedside
Expo Halls ABC (Moscone Center)
Poster Board SUN-542
Prescription testosterone (T) has a narrow range of approved medical indications and is a controlled substance in Canada and elsewhere due to its potential for misuse and abuse. Despite sharp increases in sales volume and the advent of direct-to-consumer advertising for T in the U.S., there is little information regarding population-based patterns of androgen use in developed countries. Using data based on electronic records of dispensed prescriptions, we conducted a population-based study (1976-2008) to examine medical use of androgens, including T, among adult (18+) men in Saskatchewan, Canada: a jurisdiction of universal health care. Over the 32-year study, data were missing for an 18-month period (July 1987-Dec 1988). To examine time trends, we calculated annual androgen prescription dispensing event rates per 18+ male population per year using provincial census data. There were 11,521 men who used androgens during the study period. Only injected and orally-administered formulations of androgens were listed in the provincial formulary. Overall, 11 types of androgens were used and 86,812 prescriptions were dispensed. The mean age at first use was 56.4 (median: 58). Men were dispensed 7.5 prescriptions on average (median: 2); 89.9% were prescribed by a general practitioner. The most commonly-used formulations were methyl-T (36.2% of users) followed by T-enanthate (32.5%), T-cypionate (22.3%) and T-undecanoate (20.0%). Most users (82%) did not switch among androgen types. Over the first 20 years of the study period, the annual rate of prescription dispensing events per population was relatively constant (approximately 5.0 per 1000), but began to increase from 1997-98, and thereafter remained >10.0 per 1000 from 1999-2008. Our population-based study adds to the scant epidemiologic literature on androgen utilization and suggests increasing use of androgens over time.
Disclosure: GAW: Researcher, Bayer, Inc., Researcher, Eli Lilly & Company, Board Member, Eli Lilly & Company, Researcher, Eli Lilly & Company, Researcher, Bayer, Inc., Researcher, Novo Nordisk, Researcher, Lawley Pharmaceuticals, Consultant, Lawley Pharmaceuticals. Nothing to Disclose: ABA, GR, LJT, JLL, VK, PWK, SAH
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
Sources of Research Support:
NIH grant 5R21CA143170-03 awarded to SAH.